<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03863535</url>
  </required_header>
  <id_info>
    <org_study_id>Ruijin Hospital</org_study_id>
    <nct_id>NCT03863535</nct_id>
  </id_info>
  <brief_title>PRP vs PRP+IVC for Severe nPDR</brief_title>
  <official_title>Panretinal Photocoagulation (PRP) vs PRP Combined With Intravitreous Conbercept (IVC) for Severe Nonproliferative Diabetic Retinopathy (nPDR): A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Municipal Science and Technology Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The randomized clinical trial aims to compare the therapeutic effects between panretinal
      photocoagulation(PRP) and PRP combined with intravitreal conbercept (IVC) injection in severe
      nPDR with/without diabetic macular edema patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a prospective, randomized, two-armed study to assess the efficacy and safety of
      intravitreal conbercept injection plus PRP versus PRP in the treatment of nPDR patients
      with/without diabetic macular edema for a period of 1 year. This was an
      investigator-initiated study performed by department of ophthalmology, Ruijin hospital
      affiliated with Shanghai Jiaotong University School of Medicine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in best-corrected visual acuity (BCVA)</measure>
    <time_frame>from baseline to month 12</time_frame>
    <description>To assess the effects of two therapies on visual acuity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in central subfield thickness</measure>
    <time_frame>from baseline to month 12</time_frame>
    <description>optical coherence tomography (OCT) for the assessment of central macular thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fundus fluorescein angiography</measure>
    <time_frame>from baseline to month 12</time_frame>
    <description>fluorescein angiography to measure area of fluorescein leakage (FLA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Foveal avascular zone</measure>
    <time_frame>from baseline to month 12</time_frame>
    <description>Optical coherence tomography angiography (OCTA) for measurement of FAZ</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Severe Nonproliferative Diabetic Retinopathy</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Diabete Mellitus</condition>
  <arm_group>
    <arm_group_label>Intravitreal conbercept+Panretinal coagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panretinal coagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conbercept</intervention_name>
    <description>Participants were randomized (1:1) to receive IVC+PRP or PRP monotherapy. Patients in IVC+PRP group with diabetic macular edema (DME) received 3 monthly IVC injections along with standard PRP within 1 week after the first injection. Those without DME received 1 lVC injection and standard PRP within 1 week after the injection . Re-treatments in both groups were at the investigators'discretion.</description>
    <arm_group_label>Intravitreal conbercept+Panretinal coagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Panretinal coagulation</intervention_name>
    <description>The PRP monotherapy group received standard PRP between day 1 and month 2; thereafter, re-treatments in both groups were at the investigators'discretion.</description>
    <arm_group_label>Intravitreal conbercept+Panretinal coagulation</arm_group_label>
    <arm_group_label>Panretinal coagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Type II diabetic patients, 18 years and older, were included if the participants had:

          1. severe non-PDR in either eyes with/without diabetic macular edema;

          2. ETDRS letters-measured best-corrected visual acuity (BCVA) ranging from 20/40 to
             20/320 Snellen equivalent;

          3. no previous treatment (of any type) in either eye.

        Exclusion Criteria:

          1. history of prior laser treatment or vitrectomy in the study eye;

          2. history of thromboembolic event - including myocardial infarction or cerebral vascular
             accident;

          3. major surgery within the prior 6 months or planned within the next 28 days;

          4. history of glaucoma or ocular hypertension;

          5. loss of vision as a result of other causes;

          6. history of systemic corticosteroid therapy within the last 3 months;

          7. severe systemic disease other than diabetes mellitus;

          8. known coagulation abnormalities or current use of anticoagulative medication other
             than aspirin

          9. any condition that could affect followup or documentation (including preretinal or
             vitreous hemorrhage).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xi Shen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qiong Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xi Shen, MD</last_name>
    <phone>+86-021-64370045</phone>
    <email>carl_shen2005@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>20025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xi Shen, PhD</last_name>
      <phone>+86 136-2167-7680</phone>
      <email>carl_shen2005@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>March 3, 2019</last_update_submitted>
  <last_update_submitted_qc>March 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Xi Shen</investigator_full_name>
    <investigator_title>Department director of Ophthamology</investigator_title>
  </responsible_party>
  <keyword>Conbercept</keyword>
  <keyword>Panretinal photocoagulation</keyword>
  <keyword>non-proliferative diabetic retinopathy</keyword>
  <keyword>diabetic macular edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

